Difference between revisions of "Anal squamous cell carcinoma"

Line 65:

*CDX2 -ve/+ve.

**May be useful to differentiate from [[vulva]] and [[penis]].<ref name=pmid23105122>{{Cite journal | last1 = Gunia | first1 = S. | last2 = Koch | first2 = S. | last3 = May | first3 = M. | title = Is CDX2 immunostaining useful for delineating anorectal from penile/vulvar squamous cancer in the setting of squamous cell carcinoma with clinically unknown primary site presenting with histologically confirmed inguinal lymph node metastasis? | journal = J Clin Pathol | volume = 66 | issue = 2 | pages = 109-12 | month = Feb | year = 2013 | doi = 10.1136/jclinpath-2012-201138 | PMID = 23105122 }}</ref>

*PD-L1 +ve in ~40% of cases.<ref name=pmid34790403>{{cite journal |authors=Armstrong SA, Malley R, Wang H, Lenz HJ, Arguello D, El-Deiry WS, Xiu J, Gatalica Z, Hwang JJ, Philip PA, Shields AF, Marshall JL, Salem ME, Weinberg BA |title=Molecular characterization of squamous cell carcinoma of the anal canal |journal=J Gastrointest Oncol |volume=12 |issue=5 |pages=2423–2437 |date=October 2021 |pmid=34790403 |pmc=8576238 |doi=10.21037/jgo-20-610 |url=}}</ref>

**PD-1 expressed in nearly 70% of tumours.<ref name=pmid34790403/>

==Sign out==

Line 71:

Line 73:

- INVASIVE SQUAMOUS CELL CARCINOMA.

</pre>

Note:

*There is no CAP Cancer Protocol Template.

*AJCC staging is based on size of the tumour.<ref>URL: [https://www.cancer.org/cancer/types/anal-cancer/detection-diagnosis-staging/staging.html https://www.cancer.org/cancer/types/anal-cancer/detection-diagnosis-staging/staging.html]. Accessed on: June 26, 2023.</ref>

==See also==

Difference between revisions of "Anal squamous cell carcinoma"

Navigation menu

Search

@@ Line 65: / Line 65: @@
 *CDX2 -ve/+ve.
 **May be useful to differentiate from [[vulva]] and [[penis]].<ref name=pmid23105122>{{Cite journal  | last1 = Gunia | first1 = S. | last2 = Koch | first2 = S. | last3 = May | first3 = M. | title = Is CDX2 immunostaining useful for delineating anorectal from penile/vulvar squamous cancer in the setting of squamous cell carcinoma with clinically unknown primary site presenting with histologically confirmed inguinal lymph node metastasis? | journal = J Clin Pathol | volume = 66 | issue = 2 | pages = 109-12 | month = Feb | year = 2013 | doi = 10.1136/jclinpath-2012-201138 | PMID = 23105122 }}</ref>
+*PD-L1 +ve in ~40% of cases.<ref name=pmid34790403>{{cite journal |authors=Armstrong SA, Malley R, Wang H, Lenz HJ, Arguello D, El-Deiry WS, Xiu J, Gatalica Z, Hwang JJ, Philip PA, Shields AF, Marshall JL, Salem ME, Weinberg BA |title=Molecular characterization of squamous cell carcinoma of the anal canal |journal=J Gastrointest Oncol |volume=12 |issue=5 |pages=2423–2437 |date=October 2021 |pmid=34790403 |pmc=8576238 |doi=10.21037/jgo-20-610 |url=}}</ref>
+**PD-1 expressed in nearly 70% of tumours.<ref name=pmid34790403/>
 ==Sign out==
@@ Line 71: / Line 73: @@
 - INVASIVE SQUAMOUS CELL CARCINOMA.
 </pre>
+Note:
+*There is no CAP Cancer Protocol Template.
+*AJCC staging is based on size of the tumour.<ref>URL: [https://www.cancer.org/cancer/types/anal-cancer/detection-diagnosis-staging/staging.html https://www.cancer.org/cancer/types/anal-cancer/detection-diagnosis-staging/staging.html]. Accessed on: June 26, 2023.</ref>
 ==See also==